Pharmasyntez-Nord JSC expanded the list of antineoplastic drugs produced. Drug product Brestoker was registered in July 2023 and is intended for the treatment of adult patients with breast cancer. This is the first drug with the active ingredient Lapatinib manufactured in St. Petersburg. 

The action of the drug is based on blocking a certain protein produced by the disease, which helps to slow the growth of cancer cells. Lapatinib is a reversible tyrosine kinase inhibitor that allows for targeted therapy of breast cancer. The benefits of targeted therapy include its high efficacy and milder side effect profile compared to other treatments such as chemotherapy. 

Brestoker may be used in monotherapy for patients with metastatic breast cancer, as well as in complex treatment regimens in combination with aromatase inhibitors or other targeted drugs also manufactured by Pharmasyntez-Nord JSC. 

Pharmasyntez-Nord's portfolio already includes many drug products that are successfully used in most treatment regimens for various forms of breast cancer. Furthermore, the company produces other effective targeted drugs for the treatment of malignant tumors of other localizations. 

In total, Pharmasyntez-Nord produces 45 trade names of oncological drugs in the volume of 5.6 million packs per year. 99% of the manufactured products are included in the List of Vital and Essential Drugs of the Ministry of Health of the Russian Federation. 

Pharmasyntez-Nord JSC is a modern Russian company for the development and production of innovative drugs and effective analogs of imported medicines. Pharmasyntez-Nord operates in accordance with the requirements of Good Manufacturing Practice (GMP). The quality system is in place at all stages of the drug life cycle and is based on the principles of continuous improvement and risk-oriented approach.